![Jean-Claude Martinez](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Jean-Claude Martinez first degree
Entity | Entity type | Industry | |
---|---|---|---|
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.
19
| Private Company | Investment Managers | 19 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jean-Claude Martinez via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
InfoVista SAS
![]() InfoVista SAS Packaged SoftwareTechnology Services InfoVista SAS is engaged in providing software developer solutions. It designs and develops software, which monitors, analyzes and reports on the performance of service of information technology infrastructure, including networks, servers and applications. The company was founded in 1996 and is headquartered in Les Ulis, France. | Packaged Software | Chairman | |
TOUCHSTONE INNOVATIONS PLC | Investment Managers | Corporate Officer/Principal | |
Stanford University | College/University | Masters Business Admin | |
Novo Holdings AS (Denmark)
![]() Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer | |
Rochester Institute of Technology
![]() Rochester Institute of Technology Other Consumer ServicesConsumer Services Rochester Institute of Technology is a privately endowed, coeducational university with ten colleges emphasizing career education and experiential learning. It was founded in 1829 and is headquartered in Rochester, NY. | College/University | Undergraduate Degree | |
LEGUIDE.COM | Internet Software/Services | Chief Executive Officer Corporate Officer/Principal | |
Streamezzo SA
![]() Streamezzo SA Information Technology ServicesTechnology Services Streamezzo SA develops software solutions for mobile phone. It develops platforms, that enable multimedia application deployment. The company was founded by Jean-Claude Dufourd, Cédric Gégout, and Olivier Avaro on February 4, 2004 and is headquartered in Rennes, France. | Information Technology Services | Chairman Director/Board Member | |
VERIMATRIX | Semiconductors | Director/Board Member Director/Board Member | |
6Wind SA
![]() 6Wind SA Packaged SoftwareTechnology Services 6Wind SA provides software development services. It provides solutions in network function virtualization, software define networking, data center, network appliance, network security, and TCP application. The firm products are 6Wind virtual accelerator, turbo router, turbo IPsec and 6Windgate. The company was founded by Eric Carm?s in July 2000 and is headquartered in Montigny-le-Bretonneux, France. | Packaged Software | Director/Board Member Director/Board Member | |
IP2IPO Innovations Ltd.
![]() IP2IPO Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services IP2IPO Innovations Ltd. provides business development and technology transfer services. The firm also provides strategic industry University partnerships, patenting, licensing, spin-out incubation and equity management services. The company was founded in 1986 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Politecnico di Milano | College/University | Graduate Degree | |
ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree | |
ESCP Europe Campus Paris | College/University | Masters Business Admin | |
Touchstone Innovations Investment Management Ltd.
![]() Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Stanmore Implants Worldwide Ltd.
![]() Stanmore Implants Worldwide Ltd. Medical SpecialtiesHealth Technology Stanmore Implants Worldwide, Ltd. designs and manufactures bespoke and modular implants for limb sparing and complex joint replacement. It provides massive endoprothesis tumour systems for orthopedic skeletal locations including the femur, tibia, knee, pelvis and humerus. The firm also offers computer assisted orthopedic surgeries. The company was founded on February 19, 1996 and is headquartered in Elstree, the United Kingdom. | Medical Specialties | Director/Board Member | |
Serena Capital SAS
![]() Serena Capital SAS Investment ManagersFinance Serena Capital SAS is an Independent Venture Capital firm founded in 2008 by Marc Fournier, Philippe Hayat and Xavier Lorphelin. Serena Capital SAS is headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
EpiTherapeutics ApS
![]() EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
MD Start SA
![]() MD Start SA BiotechnologyHealth Technology MD Start SA develops medical device technology. It has collaboration between venture capital, institutional investors and industry to the development of innovative medtech ideas in Europe. The company was founded by Tim Lenihanin 2010 and is headquartered in Paris, France. | Biotechnology | Chief Investment Officer | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member | |
ReCor Medical, Inc.
![]() ReCor Medical, Inc. Pharmaceuticals: MajorHealth Technology ReCor Medical, Inc. develops novel therapeutic ultrasound catheter technologies The firm develops a therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The company was founded by Mano Iyer and Jacques Seguin in July 2009 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Founder | |
Eclaircile Gestion SAS | Investment Managers | Private Equity Investor | |
Nascient Ltd.
![]() Nascient Ltd. BiotechnologyHealth Technology Nascient Ltd. develops a novel antibody treatment for rheumatoid arthritis. The company was founded by Phil Bland-Ward, Kim Midwood and Nigel Robert Burns in 2012 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Jolt Capital SAS
![]() Jolt Capital SAS Investment ManagersFinance Jolt Capital SAS (Jolt Capital) is an independent private equity firm founded in 2011 by Jean Schmitt. The firm is headquartered in Paris, France. | Investment Managers | Founder Private Equity Investor | |
Aledia SAS
![]() Aledia SAS Electrical ProductsProducer Manufacturing Aledia SAS develops and manufactures light-emitting diodes. Its products are based on 3D architecture using gallium-nitride-on-silicon microwires. The firm's technology uses silicon wafers and existing complementary metal-oxide semiconductor wafer-fabrication processes and tools, enabling production of LED chips. The company was founded by Giorgio Anania, Philippe Gilet, and Xavier Hugon in 2011 and is headquartered in Grenoble, France. | Electrical Products | Director/Board Member | |
Asceneuron SA
![]() Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Avilex Pharma ApS
![]() Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
HighLife SAS
![]() HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
AFYREN | Biotechnology | Director/Board Member Director/Board Member | |
GreenTropism SAS
![]() GreenTropism SAS Packaged SoftwareTechnology Services GreenTropism SAS develops embedded software. It offers library of models and database services. The company was founded by Anthony Boulanger in 2014 and is headquartered in Paris, France. | Packaged Software | Director/Board Member Chairman | |
Delinea, Inc. (United States)
![]() Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Biotechnology | Director/Board Member | |
iOmx Therapeutics AG
![]() iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member | |
Obsidian Therapeutics, Inc.
![]() Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
BiomX Ltd.
![]() BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Pharmaceuticals: Major | Director/Board Member | |
NodThera Ltd.
![]() NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Nitrase Therapeutics, Inc.
![]() Nitrase Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nitrase Therapeutics, Inc. develops drugs against newly discovered nitration enzyme. The firm provides disease modifying drugs for multiple additional aging-dependent diseases, such as neurodegenerative disease, heart disease and cancer. The company was founded by Irene Griswold-Prenner and is headquartered in Jackson, WY. | Miscellaneous Commercial Services | Director/Board Member | |
Redona Therapeutics, Inc.
![]() Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
Comet Therapeutics, Inc.
![]() Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
BIOMX INC. | Biotechnology | Director/Board Member | |
Muna Therapeutics ApS
![]() Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
Mozart Therapeutics, Inc.
![]() Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Biotechnology | Director/Board Member | |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman | |
Inivata Ltd.
![]() Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Packaged Software | Director/Board Member | |
Comet Biorefining, Inc.
![]() Comet Biorefining, Inc. BiotechnologyHealth Technology Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada. | Biotechnology | Director/Board Member Director/Board Member |
Statistics
International
France | 16 |
United States | 11 |
United Kingdom | 8 |
Denmark | 8 |
Switzerland | 4 |
Sectoral
Health Technology | 23 |
Technology Services | 8 |
Finance | 8 |
Consumer Services | 6 |
Electronic Technology | 4 |
Operational
Director/Board Member | 133 |
Private Equity Investor | 29 |
Chairman | 22 |
Corporate Officer/Principal | 22 |
President | 12 |
Most connected contacts
Insiders | |
---|---|
Jean Schmitt | 35 |
Olivier Sichel | 25 |
Henrijette Richter | 21 |
Nicolas Autret | 19 |
Joško Bobanovic | 19 |
Dan Newman | 17 |
Robert Woodman | 14 |
Alain Tingaud | 13 |
Michael Krel | 13 |
Jean-Bernard Schmidt | 13 |
Ram Aiyar | 12 |
Alessio Beverina | 12 |
Katie Ellias | 11 |
Ha-Jin Shin-de Bruchard | 7 |
Mano Iyer | 6 |
- Stock Market
- Insiders
- Jean-Claude Martinez
- Company connections